JP2024525566A5 - - Google Patents
Info
- Publication number
- JP2024525566A5 JP2024525566A5 JP2024500249A JP2024500249A JP2024525566A5 JP 2024525566 A5 JP2024525566 A5 JP 2024525566A5 JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024525566 A5 JP2024525566 A5 JP 2024525566A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cancer
- pharmaceutical composition
- composition according
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220006P | 2021-07-09 | 2021-07-09 | |
| US63/220,006 | 2021-07-09 | ||
| PCT/US2022/034493 WO2023283049A1 (en) | 2021-07-09 | 2022-06-22 | Pharmaceutical compositions of a pd-1 antibody and use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525566A JP2024525566A (ja) | 2024-07-12 |
| JP2024525566A5 true JP2024525566A5 (https=) | 2025-06-30 |
Family
ID=82608118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500249A Pending JP2024525566A (ja) | 2021-07-09 | 2022-06-22 | Ｐｄ‐１抗体の医薬組成物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12364756B2 (https=) |
| EP (1) | EP4366692A1 (https=) |
| JP (1) | JP2024525566A (https=) |
| KR (1) | KR20240035533A (https=) |
| CN (1) | CN118215465A (https=) |
| AR (1) | AR126404A1 (https=) |
| AU (1) | AU2022307332A1 (https=) |
| CA (1) | CA3224640A1 (https=) |
| CL (1) | CL2024000077A1 (https=) |
| CO (1) | CO2024000198A2 (https=) |
| CR (1) | CR20240065A (https=) |
| EC (1) | ECSP24008791A (https=) |
| IL (1) | IL309985A (https=) |
| MX (1) | MX2024000268A (https=) |
| PE (1) | PE20240797A1 (https=) |
| TW (1) | TW202308694A (https=) |
| WO (1) | WO2023283049A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| HUE068868T2 (hu) * | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN114632150B (zh) * | 2017-11-02 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 一种抗pd-l1人源化单克隆抗体的药物组合物 |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| KR20220044527A (ko) | 2019-08-01 | 2022-04-08 | 인사이트 코포레이션 | Ido 억제제의 투여 요법 |
| KR20220041099A (ko) | 2019-08-05 | 2022-03-31 | 오노 야꾸힝 고교 가부시키가이샤 | 면역 체크포인트 저해약의 유효성 판정 바이오마커 |
-
2022
- 2022-06-22 CA CA3224640A patent/CA3224640A1/en active Pending
- 2022-06-22 KR KR1020247004643A patent/KR20240035533A/ko active Pending
- 2022-06-22 PE PE2024000052A patent/PE20240797A1/es unknown
- 2022-06-22 MX MX2024000268A patent/MX2024000268A/es unknown
- 2022-06-22 AU AU2022307332A patent/AU2022307332A1/en active Pending
- 2022-06-22 CN CN202280059325.XA patent/CN118215465A/zh active Pending
- 2022-06-22 CR CR20240065A patent/CR20240065A/es unknown
- 2022-06-22 IL IL309985A patent/IL309985A/en unknown
- 2022-06-22 EP EP22744039.3A patent/EP4366692A1/en active Pending
- 2022-06-22 WO PCT/US2022/034493 patent/WO2023283049A1/en not_active Ceased
- 2022-06-22 US US17/847,094 patent/US12364756B2/en active Active
- 2022-06-22 JP JP2024500249A patent/JP2024525566A/ja active Pending
- 2022-07-05 TW TW111125067A patent/TW202308694A/zh unknown
- 2022-07-07 AR ARP220101785A patent/AR126404A1/es unknown
-
2024
- 2024-01-09 CL CL2024000077A patent/CL2024000077A1/es unknown
- 2024-01-11 CO CONC2024/0000198A patent/CO2024000198A2/es unknown
- 2024-02-02 EC ECSENADI20248791A patent/ECSP24008791A/es unknown
-
2025
- 2025-07-21 US US19/275,898 patent/US20250345422A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| JP2014132009A5 (https=) | ||
| JP2022533578A5 (https=) | ||
| JP2012500180A5 (https=) | ||
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| ES2899636T3 (es) | Tinostamustina para su uso en el tratamiento de cáncer de ovario | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| WO2019057141A1 (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP6029808B2 (ja) | 併用療法における（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の使用方法 | |
| JP2023513297A5 (https=) | ||
| JP2024513575A (ja) | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 | |
| WO2025157289A1 (zh) | 包含prmt5抑制剂和krasg12c抑制剂的药物组合物 | |
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| JP6063472B2 (ja) | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 | |
| ES2330324T3 (es) | Derivados del epotilon para el tratamiento del hepatoma y de otros canceres. | |
| ES2685974T3 (es) | Derivados de cefalosporina para tratar el cáncer | |
| ES2854298T3 (es) | Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1 | |
| TW202114694A (zh) | 四環化合物及其鹽類、組合物、及彼等之使用方法 | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| JP2022519923A5 (https=) | ||
| US20220062294A1 (en) | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts | |
| JP2024525566A5 (https=) | ||
| JP7381115B2 (ja) | 組成物及びがん治療用医薬品の調製におけるその応用 |